SCHEMBL2968950

SCHEMBL2968950

COc1ccc(-c2oc3ncnc(O)c3c2-c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.74
ALDH1A1 P00352 1/20 0.74
HPGD P15428 1/20 0.74
UBE2N P61088 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
TEK Q02763 9/20 0.65
KDR P35968 6/20 0.65
CHEK1 O14757 2/20 0.58
CDK1 P06493 1/20 0.58
GSK3B P49841 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TNK2 Q07912 2/20 0.56
AURKA O14965 1/20 0.53
POLB P06746 1/20 0.52
RAD52 P43351 1/20 0.52
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14020859 1.00 KDM4E (0.74) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL2976986 0.88 TNK2 (0.68) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL13271833 0.86 KDM4E (0.76) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL14923113 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL1785974 0.85 KDM4E (0.74) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL12355051 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL2975999 0.85 KDM4E (0.74) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL14923114 0.83 KDM4E (0.71) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL4530280 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2
SCHEMBL14463690 0.82 KDM4E (0.63) KDM4EALDH1A1HPGDUBE2NSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP disclosed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US disclosed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 KDM4E 3284/4885ALDH1A1 159/4885HPGD 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.